World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
100
Citations
61265
World Ranking
8114
National Ranking
795

Overview

Ian W. Flinn is affiliated with the Sarah Cannon Research Institute in the United Kingdom. Their research primarily focuses on the field of medicine, with significant contributions across several subfields including genetics, pathology and forensic medicine, oncology, immunology, and hematology.

The scientist's research addresses a variety of topics, with particular attention to chronic lymphocytic leukemia research, lymphoma diagnosis and treatment, and CAR-T cell therapy research. Additional topics of interest include chronic myeloid leukemia treatments, biosimilars and bioanalytical methods, monoclonal and polyclonal antibodies research, and immunodeficiency and autoimmune disorders.

Recent publications by Ian W. Flinn include:

  • KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma, 2020, New England Journal of Medicine
  • Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma, 2021, New England Journal of Medicine
  • Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial, 2020, The Lancet
  • Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma, 2021, New England Journal of Medicine
  • Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study, 2021, The Lancet

The scientist collaborates frequently with several coauthors, including Wojciech Jurczak, Paolo Ghia, Jeff P. Sharman, Constantine S. Tam, and Nirav N. Shah.

Ian W. Flinn is also a frequent contributor to multiple academic journals. The most common publication venues are:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • HemaSphere
  • Hematological Oncology

Best Publications

  • Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    Sattva S. Neelapu;Frederick L. Locke;Nancy L. Bartlett;Lazaros J. Lekakis

  • Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Ian W. Flinn

  • Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

    Frederick L Locke;Armin Ghobadi;Caron A Jacobson;David B Miklos

  • Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

    Richard R. Furman;Jeff P. Sharman;Steven E. Coutre;Bruce D. Cheson

  • Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

    Eytan M. Stein;Eytan M. Stein;Courtney D. DiNardo;Daniel A. Pollyea;Amir T. Fathi

  • KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

    Michael Wang;Javier Munoz;Andre Goy;Frederick L. Locke

  • Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

    Michael J. Keating;Ian Flinn;Vinay Jain;Jacques-Louis Binet

  • ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia

    Laura Z. Rassenti;Lang Huynh;Tracy L. Toy;Liguang Chen

  • PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

    Ajay K. Gopal;Ajay K. Gopal;Brad S. Kahl;Sven de Vos;Nina D. Wagner-Johnston

  • CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.

    Ranjana Advani;Ian Flinn;Leslie Popplewell;Andres Forero

  • Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

    Jorge E Cortes;Hagop M Kantarjian;Neil P. Shah;Dale Bixby

  • Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma

    Thomas E. Witzig;Ian W. Flinn;Leo I. Gordon;Christos Emmanouilides

  • Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.

    A. Hochhaus;G. Saglio;Timothy Hughes;R. A. Larson

  • Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

    Jennifer R. Brown;John C. Byrd;Steven E. Coutre;Don M. Benson

  • Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

    Hagop M. Kantarjian;Andreas Hochhaus;Giuseppe Saglio;Carmino De Souza

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

    John C. Byrd;Timothy Murphy;Robin S. Howard;Margaret S. Lucas

  • Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

    Gerard Lozanski;Nyla A. Heerema;Ian W. Flinn;Lisa Smith

  • Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997

    Ian W. Flinn;Donna S. Neuberg;Michael R. Grever;Gordon W. Dewald

  • Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.

    Eytan M. Stein;Courtney Denton Dinardo;Daniel Aaron Pollyea;Amir Tahmasb Fathi

Frequent Co-Authors

John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Steven Coutre
Steven Coutre Stanford University
Richard R. Furman
Richard R. Furman NewYork–Presbyterian Hospital
Thomas J. Kipps
Thomas J. Kipps University of California, San Diego
Susan O'Brien
Susan O'Brien University of California, Irvine
John P. Leonard
John P. Leonard Cornell University
Paolo Ghia
Paolo Ghia Vita-Salute San Raffaele University
John G. Gribben
John G. Gribben Queen Mary University of London
Jan A. Burger
Jan A. Burger The University of Texas MD Anderson Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring a career in medicine, a variety of online degree options and alternative paths are available to help you reach your goals. For those interested in advanced nursing but don’t hold a nursing background, consider direct entry np programs for non nurses online. These programs enable career changers to become nurse practitioners more quickly by providing a streamlined route into the field.

Entry into traditional nursing programs can be highly competitive, but some nursing schools with high acceptance rates offer more accessible pathways. These schools may be ideal for students seeking flexible options and a supportive admission process.

Beyond nursing, other healthcare roles such as medical billing and coding are also in demand. Many accredited institutions offer online medical billing and coding with financial aid, making it easier to start a healthcare career without a clinical background.

Some nursing programs reduce barriers even further by offering enrollment with no standardized exam requirements. Consider a nursing school no entrance exam to streamline your application process and begin your studies sooner.

Best Scientists Citing Ian W. Flinn

Trending Scientists

Recently Published Articles